IL213358A0 - Antibody design using anti-lipid antibody crystal structures - Google Patents

Antibody design using anti-lipid antibody crystal structures

Info

Publication number
IL213358A0
IL213358A0 IL213358A IL21335811A IL213358A0 IL 213358 A0 IL213358 A0 IL 213358A0 IL 213358 A IL213358 A IL 213358A IL 21335811 A IL21335811 A IL 21335811A IL 213358 A0 IL213358 A0 IL 213358A0
Authority
IL
Israel
Prior art keywords
antibody
crystal structures
lipid
design
antibody design
Prior art date
Application number
IL213358A
Other languages
English (en)
Original Assignee
Lpath Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lpath Inc filed Critical Lpath Inc
Publication of IL213358A0 publication Critical patent/IL213358A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL213358A 2008-12-05 2011-06-05 Antibody design using anti-lipid antibody crystal structures IL213358A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12031808P 2008-12-05 2008-12-05
US15589509P 2009-02-26 2009-02-26
US23125809P 2009-08-04 2009-08-04
PCT/US2009/066862 WO2010065921A2 (en) 2008-12-05 2009-12-04 Antibody design using anti-lipid antibody crystal structures

Publications (1)

Publication Number Publication Date
IL213358A0 true IL213358A0 (en) 2011-07-31

Family

ID=42233904

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213358A IL213358A0 (en) 2008-12-05 2011-06-05 Antibody design using anti-lipid antibody crystal structures

Country Status (9)

Country Link
US (1) US20110044990A1 (enExample)
EP (1) EP2374001A4 (enExample)
JP (1) JP2012511026A (enExample)
KR (1) KR20110097923A (enExample)
CN (1) CN102573905A (enExample)
AU (1) AU2009322185A1 (enExample)
CA (1) CA2745436A1 (enExample)
IL (1) IL213358A0 (enExample)
WO (1) WO2010065921A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011153416A2 (en) * 2010-06-04 2011-12-08 Lpath, Inc. Novel anti-s1p antibody variants of lt1009
ITRM20100441A1 (it) * 2010-08-05 2012-02-06 Michele Pitaro Procedimento per la produzione di anticorpi monoclonali anti-idiotipo ad uso diagnostico e/o terapeutico
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
AU2015217149B2 (en) 2014-02-11 2020-09-10 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
BR112017007942A2 (pt) 2014-10-30 2017-12-19 Textile Based Delivery Inc sistemas de liberação
CN110698559B (zh) * 2015-12-24 2021-11-26 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
JP6778932B2 (ja) * 2016-09-16 2020-11-04 国立大学法人大阪大学 免疫実体クラスタリングソフトウェア
US11680110B2 (en) 2017-07-31 2023-06-20 Hoffmann-La Roche Inc. Three-dimensional structure-based humanization method
CN107480360B (zh) * 2017-08-03 2020-04-24 中北大学 光束细分和相界面漫反射的激光烧熔的数值计算方法
CN109837250B (zh) * 2019-01-15 2021-10-12 中国农业科学院兰州兽医研究所 羔羊睾丸支持细胞永生化细胞系及其建立方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) * 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5229275A (en) * 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
EP0626012B1 (en) * 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5573905A (en) * 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9223377D0 (en) * 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
WO1999029888A1 (en) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
WO1999045959A1 (en) * 1998-03-13 1999-09-16 Dana-Farber Cancer Institute, Inc. Humanized antibody and uses thereof
WO2000032634A1 (en) * 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
US6881546B2 (en) * 2000-12-22 2005-04-19 Medlyte, Inc., Sdsu Heart Institute Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2007038392A2 (en) * 2005-09-23 2007-04-05 Walter Reed Army Institute Of Research (Wrair) Antibodies with simultaneous subsite specificities to protein and lipid epitopes
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US9217749B2 (en) * 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
WO2008070344A2 (en) * 2006-10-27 2008-06-12 Lpath, Inc. Compositions and methods for binding sphingosine-1-phosphate
US8614103B2 (en) * 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions

Also Published As

Publication number Publication date
US20110044990A1 (en) 2011-02-24
EP2374001A2 (en) 2011-10-12
CA2745436A1 (en) 2010-06-10
KR20110097923A (ko) 2011-08-31
AU2009322185A1 (en) 2011-07-21
EP2374001A4 (en) 2013-03-13
WO2010065921A3 (en) 2011-12-29
WO2010065921A2 (en) 2010-06-10
JP2012511026A (ja) 2012-05-17
CN102573905A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
AP3371A (en) Anti-IGF antibodies
GB0903325D0 (en) Antibody molecules
SG10201401331TA (en) Anti-siglec-15 antibody
ZA201102119B (en) Improved antibody libraies
DK3091034T3 (da) Anti-CD40-antistoffer og anvendelser deraf
EP2374001A4 (en) ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES
PT2146745E (pt) Anticorpo pentaespecífico
PL3023438T3 (pl) Przeciwciała anty-gitr
GB0821100D0 (en) Antibodies
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
ZA201006099B (en) Anti-tyrp1 antibodies
IL205073A0 (en) Anti-bst2 antibody
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
GB0908006D0 (en) New crystal form
GB2473934B (en) Anti-VEEV antibody
GB2457157B (en) Crystal unit
GB0911770D0 (en) Antibody
GB0716322D0 (en) Crystal structure
GB0811620D0 (en) Crystal structure
GB0703070D0 (en) Crystal structure
EP2331133A4 (en) ANTILIPID ANTIBODIES
HK1158525A (en) Anti-lipid antibodies
GB0817622D0 (en) Antibody
GB0817621D0 (en) Antibody